Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€236.15

€236.15

-0.150%
-0.35
-0.150%
€245.80

€245.80

 
11:09 / Tradegate WKN: 866197 / Symbol: DHR / Name: Danaher / Stock / Machinery, Equipment & Components / Large Cap /
Latest predictions
€260.00
26.03.24
3.40%
buy
€268.08
01.02.24
6.13%
buy
€259.06
31.01.24
6.89%
buy
€259.89
31.01.24
6.75%
buy
€248.56
31.01.24
4.68%
buy
29.12.23
12.68%
buy
Best running prediction
€225.86
25.10.23
30.33%
buy
Your prediction

Danaher Corp. Stock

Danaher Corp. shows a slight decrease today, losing -€0.350 (-0.150%) compared to yesterday.
The stock is an absolute favorite of our community with 22 Buy predictions and no Sell predictions.
As a result the target price of 245 € shows a slightly positive potential of 3.75% compared to the current price of 236.15 € for Danaher Corp..
For the coming years our community has positive and negative things to say abot the Danaher Corp. stock. Criterium "Revenue growth" gathered the most positive votes but regarding "Debt" there were negative voices in the community.

Pros and Cons of Danaher Corp. in the next few years

Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Danaher Corp. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Danaher Corp. -0.150% 4.507% 0.297% 2.781% 12.726% 10.102% 107.493%
Stanley Black & Decker Inc. -0.140% -0.141% -3.219% 16.456% -5.401% -50.952% -35.391%
IDEX Corp. 1.150% 0.556% -4.194% 9.513% 10.573% 16.043% -
Parker-Hannifin 0.470% 0.390% 0.156% 76.225% 22.681% 95.589% 203.839%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Danaher Corporation, with the US trading symbol DHR, is a major player in the Machinery, Equipment & Components industry. After evaluating its financial statements, one can generally conclude that the company has shown remarkable growth and strength over the past few years. With a solid balance sheet and consistent cash flow generation, Danaher appears to be positioned well for future growth. However, as with any company, there are certain aspects that warrant close attention.

Pros

Earnings growth: Net income has shown an upward trend, growing from $3.65 billion in 2020 to $7.21 billion in 2022. This is indicative of the company's financial strength and profitability.

Comments

Prediction Buy
Perf. (%) 6.13%
Target price 268.076
Change
Ends at 01.02.25

Danaher Co. (NYSE: DHR) had its price target raised by analysts at KeyCorp from $260.00 to $290.00. They now have an "overweight" rating on the stock.
Ratings data for DHR provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 6.89%
Target price 259.056
Change
Ends at 31.01.25

Danaher Co. (NYSE: DHR) had its price target raised by analysts at Citigroup Inc. from $255.00 to $280.00. They now have a "buy" rating on the stock.
Ratings data for DHR provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 6.75%
Target price 259.891
Change
Ends at 31.01.25

Danaher Co. (NYSE: DHR) had its price target raised by analysts at Royal Bank of Canada from $254.00 to $282.00. They now have an "outperform" rating on the stock.
Ratings data for DHR provided by MarketBeat
Show more

News

Will Danaher stock hit new highs in 2024?: https://www.marketbeat.com/logos/articles/med_20240109140643_will-danaher-stock-hit-new-highs-in-2024.jpg
Will Danaher stock hit new highs in 2024?

Danaher Corporation (NYSE: DHR) shares went into a tailspin when the Abcam deal came into question, but the dip turned out to be a buying opportunity in this life-sciences company. The dip hit